Ascentage Pharma Group International ((HK:6855)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ascentage Pharma Group International is conducting a Phase Ib/II study titled ‘A Phase Ib/II Study of the Safety, Pharmacokinetic, Pharmacodynamic and Efficacy of APG-2575 Single Agent and in Combination With Other Therapeutic Agents in Patients With Relapsed/Refractory CLL/SLL.’ The study aims to evaluate the safety and effectiveness of APG-2575, both as a standalone treatment and in combination with other drugs, for patients suffering from relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).
The study tests APG-2575, an oral drug, alone and in combination with Rituximab and Ibrutinib. APG-2575 is administered daily in varying doses, while Rituximab and Ibrutinib are added in specific stages to assess combined efficacy.
This interventional study follows a non-randomized, parallel assignment model with no masking, focusing on treatment as the primary purpose. It aims to provide insights into the drug’s pharmacokinetics and pharmacodynamics.
The study began on July 21, 2020, and is currently recruiting. The primary completion date is yet to be determined, with the latest update submitted on April 15, 2025. These dates are crucial for tracking progress and anticipating results.
The study’s progress could influence Ascentage Pharma’s stock performance, as positive outcomes may boost investor confidence. It is essential to monitor developments, especially in the context of competitors in the CLL/SLL treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.